

Eyal Baror, Head of Innovalve Technologies, Edwards Lifesciences (formerly Innovalve Bio Medical CEO)

Eyal currently serves as Head of Innovalve Technologies in Edwards Lifesciences, leading all program-related activities with a multi-national team in both US and Israel centers. Since 2019 and until Innovalve's acquisition by Edwards in 2024, Eyal served as Innovalve's CEO, spearheading it from early stages of feasibility studies of its novel Transcatheter Mitral Valve Replacement technology, through effective management of R&D valve and delivery system activities, planning and executing robust regulatory and clinical strategy, resulting with highly successful clinical outcomes (both in US as well as non-US countries), culminating with negotiating a lucrative >\$300M acquisition by Edwards. Prior to Innovalve, Eyal served in leadership roles in multiple biomedical startup companies. Eyal is a graduate of the prestigious TALPIOT program, holds a B.Sc in Physics and Mathematics from Hebrew University of Jerusalem and a M.Sc in Physics from Tel-Aviv University (cum laude and summa cum laude, respectively).